Published date: 13 April 2022

Closed opportunity - This means that the contract is currently closed. The buying department may be considering suppliers that have already applied, or no suitable offers were made.


Closing: 28 April 2022, 12pm

Contract summary

Industry

  • Blood-testing reagents - 33696200

  • Blood analysers - 38434520

  • Automation system - 48921000

    • Technical testing services - 71632000

    • Test and evaluation - 73430000

    • Blood analysis services - 85111810

Location of contract

BS34 7QH

Value of contract

£50,000,000

Procurement reference

CF-0773600D0O000000rwimUAA1

Published date

13 April 2022

Closing date

28 April 2022

Closing time

12pm

Contract start date

1 April 2023

Contract end date

31 March 2033

Contract type

Service contract

Procedure type

Competitive procedure with negotiation (above threshold)

Anyone may ask to participate, but only those who are pre-selected will be invited to submit initial tenders and to negotiate.

This procedure can be used for procurements above the relevant contract value threshold.

Contract is suitable for SMEs?

No

Contract is suitable for VCSEs?

No

Description

NHSBT requires a direct contractual relationship with either the manufacturer or any other economic operator for a complete end-to-end integrated Service, which must include all the necessary Equipment, Goods, Installation, maintenance, Consumables, Reagents, Software, including an inter-operability provision with NHSBT's existing IT infrastructure, and an overall on-going support mechanism that may be required to carry out the necessary testing as stated below.
All invitro diagnostic medical devices, for example, Instruments, Consumables and Reagents must be CE/UKCA marked. GB will continue to recognise CE marking under the IVDD or IVDR until 30 June 2023 and from 1 July 2023 devices placed on the GB market must be UKCA marked under the UK MDR 2002 as amended.
The end-to-end Service must be capable of producing test results in a format that can be utilised by NHSBT's host IT system (PULSE) (or any replacement system) without the need for changes to PULSE (or any replacement system).
The Equipment should also be compatible with NHSBT's manufactured reagents and where possible, with those from third party reagent suppliers. NHSBT requires a high throughput blood and non-blood donation screening for primary blood grouping testing system(s), for ABO and Rh D typing (as a minimum DIV, DV and DVI), antibody screening and red cell phenotyping including Rh for donor blood samples. As a minimum, the Service provided must be capable of undertaking the testing of blood and non-blood donor samples and providing accurate results for the following:• ABO group• Rh phenotype D, C, c, E, e • Kell • Atypical antibody screen• High titre anti-A and anti-B screening• Red cell phenotypes S, s, Jka, Jkb (test system should include an option of Cw and M).
All test protocols must be in accordance with the Guidelines for the Blood Transfusion service in the United Kingdom (https://www.transfusionguidelines.org/red-book) and rules and guidance for pharmaceutical manufacturers and distributors. The annual estimated throughput of the NHSBT primary automated blood sample testing equipment tests approximately 1,500,000 to 1,700,000 donations (of which ca. 1500 - 2100 are non-blood donors) are tested per annum across two NHSBT testing sites, namely Manchester and Filton.
The Tenderer must also be able to accommodate technological and digital changes in the current and future such that NHSBT is able to access the state-of-the art digital developments and IT solutions in the diagnostics market.

About the buyer

Contact name

Paul Jones

Address

500, North Bristol Park
Filton, Bristol
BS34 7QH
GB

Email

paul.jones@nhsbt.nhs.uk